Cryo-Save Group N.V. (Euronext: CRYO, `Cryo-Save`, or `the Group`), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces the completion of its Indian Management Buyout.
The Group announced that it reached agreement on the crucial terms and conditions regarding the sale and purchase of 100% of the total issued and paid share capital of its Indian subsidiary Cryo-Save (India) Private Limited with a consortium including representatives of the current local management on 25 September. The management buyout, which is fully supported and agreed by the Board of Cryo-Save, was completed as per 30 October 2013.
|Cryo-Save Group||+ 31 (0) 575 548 998|
|Evi Mattil, Chief Commercial Officer and Chief Executive Officer a/i|
About Cryo-Save (www.cryo-save.com/group)
Cryo-Save, the leading international family stem cell bank, stores more than 250,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Cryo-Save has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai and South Africa.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Cryo-Save Group N.V. via Thomson Reuters ONE